mRNA Technologies, Therapeutics and Vaccines Digital Week
Key CMC information on the critical quality attributes and corresponding justification of acceptance criteria has yet to be formally established in regulatory guidance for mRNA.

In this presentation, we describe how advanced "superhero" analytics to characterize DNA templates and RNA transcripts can be deployed to build effective quality control with a focus on the Fantastic Four - Capping Efficiency, Sequencing, Poly-A Tail, Residual dsRNA - as core considerations to support CMC.

To view our on-demand webinar, please complete the following form: